NPM1 and myeloid sarcoma: Notably, NPM1 mutations were around three times more likely to be present in the MS site compared to the bone marrow on meta-analysis; however, the difference was not statistically significant [OR 2.80 (95% CI 1.32–5.95); p = 0.43].